1. 华蟾素胶囊联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效.
- Author
-
李娟, 李晓峰, 徐生志, and 唐凯
- Abstract
Objective To investigate the impacts of cinobufotalin combined with docetaxel+cisplatin chemotherapy on the disease control and the level of vascular endothelial growth factor (VEGF) in serum of patients with non-small cell lung cancer. Methods Totally 70 patients with non-small cell lung cancer admitted to Zhejiang Veteran Hospital from March 2019 to March 2022 were included. They were randomly divided into combination group (cinobufotalin combined with docetaxel+cisplatin,n=35) and control group (docetaxel+cisplatin chemotherapy alone,n=35).The disease control rates of two groups, serum VEGF level, carcinoembryonic antigen (CEA), cytokeratin 19 (CK19) and carbohydrate antigen 125 (CA125) were measured using ELISA; life quality of patients was evaluated with the KPS score; The adverse events between two groups were compared. Results The disease control rate in the combination group (33/35, 94.29%) was higher than that that of control group (25/35, 71.43%) (P<0.05). After treatment, the level of VEGF in both groups of patients decreased, and the KPS score increased (P<0.05) especially in the combination group (P<0.05). After treatment, the level of serum CEA, CA125, and CK19 of control group and combination group were obviously lower than those before treatment(P<0.05), while those in the combination group were even lower (P<0.05). The incidence of adverse events in the combination group (5/35, 14.29%) was lower than that in the control group (13/35, 37.14%) (P<0.05). Conclusions Cinobufotalin combined with docetaxel+cisplatin chemotherapy as a potential new chemotherapy significantly reduces the level of VEGF and tumor biomarkers in serum factor, improves the life quality of patients.The combined therapy is proved tobe safe. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF